Nieuwsbrief

HTA Quarterly Summer 2026

In this edition, we look at how health economic and outcomes research (HEOR) teams can use AI to streamline quality appraisals and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) compliance checks, highlighting what a closed-system Generative AI (GenAI) chatbot can reliably support and where expert judgment remains essential. We also broaden the perspective on value, exploring how innovative treatments are increasingly assessed for their wider societal and environmental impacts beyond direct clinical outcomes. Finally, we turn to Germany, sharing insights from a Cencora-sponsored initiative leveraging approved access to the National Cancer Registry (ZfKD) to enable clinically granular oncology research under rigorous governance and data protection requirements.

Article

Beyond direct health outcomes: The wider societal impact of innovative treatments

Article

Beyond public dashboards: Leveraging Germany’s National Cancer Registry for pharmaceutical research

Heard on the street


"We're seeing first signs of delayed introductions into Europe."

- Stefan Oelrich, President of the European Federation of Pharmaceutical Industries and Associations. U.S. policy has led drugmakers to delay launching some medicines in Europe, where healthcare spending is lower, to avoid putting downward pressure on prices in the $700 billion U.S. market. 

Source: Drugmakers delay some European launches with a wary eye on Trump's pricing policies | Reuters

HTA by the numbers

15
Number of ongoing Joint Clinical Assessments (JCAs). The Coordination Group on Health Technology Assessment (HTACG) estimates that it will initiate ~50 JCAs of medicines in 2026.

List of Ongoing Joint Clinical Assessments - European Commission
Health Technology Assessment – 2026 Work Programme adopted


Neem contact op met ons team

Ons ervaren team van waarde-experts creëert op basis van bewijsmateriaal, beleidsinzichten en marktinformatie effectieve strategieën voor toegang tot wereldwijde markten. We maken u wegwijs in de complexe wereld van de gezondheidszorg in verschillende delen van de wereld. Neem contact op om te ontdekken hoe we uw doelen kunnen ondersteunen.

Gerelateerde bronnen

Artikel

AI-assisted quality assessment in HEOR: What works, what doesn’t, and how to apply GenAI responsibly

Artikel

Beyond public dashboards: Leveraging Germany’s National Cancer Registry for pharmaceutical research – Insights from a ZfKD Research Initiative

Webinar

Breaking down barriers: Why early commercialization planning is key to a successful market entry strategy